Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking PCOS over time unlock better care?

NCT ID NCT07739940

Knowledge-focused Sponsor: Guangdong Women and Children Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study aims to create a large, long-term research cohort of women with polycystic ovary syndrome (PCOS). By systematically collecting follow-up data, researchers hope to understand how the condition evolves across different life stages and identify key factors that influence disease progression. The goal is to improve risk-stratified management and long-term health outcomes for women with PCOS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This research could lead to better long-term management strategies for PCOS, potentially reducing risks of diabetes, heart disease, and pregnancy complications.
What could go wrong
As an observational cohort study, it cannot prove cause and effect. Long-term follow-up may face challenges with participant retention, and findings may not apply to all PCOS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll patients diagnosed with Polycystic Ovary Syndrome (PCOS) according to the 2023 International Evidence-based Guidelines for the Assessment and Management of PCOS, as well as age- and BMI-matched healthy controls with regular menstrual cycles. Participants will be recruited from the outpatient clinics of Guangdong Women and Children Hospital. Eligible participants will be consecutively enrolled on a voluntary basis after signing informed consent. Baseline clinical data including hormonal, metabolic, and ultrasound parameters will be collected at enrollment. All participants will be followed longitudinally to assess pregnancy-related outcomes and long-term complications.

Ages

16 to 45 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

I. Diagnostic Criteria: 2023 International Evidence-based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome II. Inclusion and Exclusion Criteria: 1. PCOS Group Inclusion Criteria: Meets the above PCOS diagnostic criteria; Voluntarily signs the informed consent form; Has complete baseline clinical data (including hormonal, metabolic, and ultrasound parameters). Exclusion Criteria: Other conditions causing hyperandrogenism or ovulatory dysfunction; Use of hormonal medications within 3 months; Concurrent severe cardiac, hepatic, or renal diseases; Mental disorders that preclude compliance with follow-up. 2. Control Group Inclusion Criteria: Age- and BMI-matched healthy females; Regular menstrual cycles (21-35 days); No clinical manifestations or biochemical evidence of hyperandrogenism.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCOS (polycystic ovary syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCOS (polycystic ovary syndrome)

Contacts and locations

Locations

  • Guangdong Women and Children Hospital

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.